Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...

The opening salvo of second-quarter earnings calls this week came against President Donald Trump’s renewed calls for a tariff ...

Novartis ( NYSE: NVS) CEO Vas Narasimhan said the company has built up its U.S. inventories to help mitigate the impact of ...

Report found business relationships between telehealth and pharma companies may indirectly lead patients toward certain ...

Abbott warned on Thursday it expects more than $1 billion in financial headwinds this year from a sharp decline in COVID-19 testing demand, new U.S. tariffs, and the government's foreign aid freeze.

Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...

President Donald Trump's proposed tariffs on pharmaceuticals could lead to higher prices, higher insurance premiums, and even drug shortages, experts say.

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...